C4 Therapeutics 1 article

The therapeutic identity of C4 Therapeutics combines targeted protein degradation and TORPEDO degrader discovery platform; the organization operates as a biopharmaceutical company. The scientific portfolio of C4 Therapeutics brings together oncogenic protein elimination, IKZF1 IKZF3 protein degradation and ubiquitin proteasome system therapeutics, preserving a specific mechanistic identity. For GenoMethods, targeted protein degradation is a durable company-level marker that helps distinguish C4 Therapeutics from neighboring entities.

Drug Discovery

September 19, 2026, 9:24 AM · 4 mins read

Bristol Myers Squibb ends Orum Therapeutics AML drug after Phase I review

Bristol Myers Squibb has stopped development of Orum Therapeutics' CD33-targeted AML drug, erasing USD 80 million in milestone payments and leaving only one approved agent in the clinical-stage DAC field.